Chicago tech darling Tempus has locked down an additional $80 million in funding just six months after it announced a $70 million Series C. The round was led by T. Rowe Price and featured participation from existing investors New Enterprise Associates and Revolution Growth along with newcomer Kinship Trust Company.
“Tempus was born out of frustration with a health care system that too often let powerful data and real world evidence go to waste," said founder and CEO Eric Lefkosky in a statement. “Given the breadth and scale of our current data set, we’re in a unique position to help usher in an era of precision medicine to support patients battling disease.”
We’re in a unique position to help usher in an era of precision medicine to support patients battling disease.”
In a statement, the company said the funds would be used to grow and scale its clinical and molecular analytics platform, which organizes and analyzes unstructured data points to deliver actionable insights to treatment providers. In addition to its data, the company also offers genomic sequencing services to cancer patients.
As the company’s technology scales, its team will grow accordingly. Tempus’ headcount has more than doubled in the six months since its Series C closed, and the company isn’t planning to slow down hiring anytime soon.
“We have about 400 employees right now and are hiring 30 employees on average a month,” a company spokesperson told Built In Chicago. “We expect to continue to hire at an aggressive clip, but are especially in search of strong data science and tech talent.”
Lefkosky and Brad Keywell founded Tempus in 2015, and in a little over two years the company has raised a whopping $210 million to fund its data-driven fight against cancer. The company has partnered with nearly half the academic medical centers in the United States — in addition to independent oncologists and medical centers — and recently announced it was teaming up with CancerLinQ, a not-for-profit health information platform that’s a subsidiary of the American Society of Clinical Oncology.